MedTrace Logo

Phase IIb Study of STA-2 in Patients With Chronic Stable Angina

NCT01239511 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 186

Last updated 2014-08-27

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the dose-response of three different dose levels of STA-2 (900 mg daily, 1800 mg daily and 2700 mg daily for 42 days) versus placebo in patients with chronic stable angina.

Conditions

  • Chronic Stable Angina

Interventions

DRUG

green tea polyphenols (STA-2)

2 capsules t.i.d., after meal

Sponsors & Collaborators

  • Sinphar Pharmaceutical Co., Ltd

    lead OTHER

Principal Investigators

  • Chuen-Den Tseng, MD, Ph.D · Department of Cardiology National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01239511 on ClinicalTrials.gov